Outcome of the Board Meeting held on 23rd May, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.9 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Amkay Products Limited, at its meeting on 23rd May 2025, approved the audited financial results for the half-year and full year ended 31st March 2025. Revenue from operations grew about 23.6% YoY to Rs. 3,839.01 lakhs (vs Rs. 3,106.91 lakhs in FY24). Total income stood at Rs. 3,970.84 lakhs vs Rs. 3,231.83 lakhs, a ~22.9% rise. Profit Before Tax grew to Rs. 429.77 lakhs from Rs. 350.10 lakhs (~22.8% growth). Profit After Tax was Rs. 263.00 lakhs, with basic EPS at Rs. 3.96 (down from Rs. 4.13 in FY24, largely due to higher share capital post-listing). The Board also appointed M/s Pimple & Associates as Secretarial Auditor and M/s Soni Punit & Associates as Internal Auditor for FY26. The statutory auditor M/s R K Jagetiya & Co issued an unmodified (clean) opinion on the results.
Positive: Strong double-digit revenue and PBT growth shows healthy business expansion. Mild watchpoint: EPS declined marginally on YoY basis due to equity dilution from the recent listing, which may pressure per-share returns in the short term.